Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Equity (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Return on Equity for 10 consecutive years, with 16.06% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 1609.0% to 16.06% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 16.06% through Dec 2025, up 1609.0% year-over-year, with the annual reading at 6.5% for FY2025, 648.0% down from the prior year.
  • Return on Equity for Q4 2025 was 16.06% at Ultragenyx Pharmaceutical, up from 0.22% in the prior quarter.
  • The five-year high for Return on Equity was 16.06% in Q4 2025, with the low at 7.95% in Q3 2023.
  • Average Return on Equity over 5 years is 0.19%, with a median of 0.29% recorded in 2021.
  • The sharpest move saw Return on Equity crashed -676bps in 2023, then soared 1609bps in 2025.
  • Over 5 years, Return on Equity stood at 0.49% in 2021, then tumbled by -252bps to 1.73% in 2022, then soared by 101bps to 0.01% in 2023, then crashed by -278bps to 0.02% in 2024, then skyrocketed by 69156bps to 16.06% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 16.06%, 0.22%, and 0.2% for Q4 2025, Q3 2025, and Q2 2025 respectively.